337 related articles for article (PubMed ID: 22298803)
1. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
2. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
3. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.
Curtis JR; Westfall AO; Allison J; Becker A; Melton ME; Freeman A; Kiefe CI; MacArthur M; Ockershausen T; Stewart E; Weissman N; Saag KG
Arch Intern Med; 2007 Mar; 167(6):591-6. PubMed ID: 17389291
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
5. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Feldstein AC; Elmer PJ; Nichols GA; Herson M
Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
[TBL] [Abstract][Full Text] [Related]
6. Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital.
Suda M; Suyama Y; Ohde S; Tsuda T; Sawada H; Kishimoto M; Okada M
Int J Rheum Dis; 2018 May; 21(5):975-981. PubMed ID: 29878618
[TBL] [Abstract][Full Text] [Related]
7. Barriers in the management of glucocorticoid-induced osteoporosis.
Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
[TBL] [Abstract][Full Text] [Related]
8. Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Song BW; Kim AR; Kim MA; Kim HS; Lee SG
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208647
[No Abstract] [Full Text] [Related]
9. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-induced osteoporosis: unawareness or negligence in India?
Gera C; Vij AS
Int J Rheum Dis; 2009 Sep; 12(3):230-3. PubMed ID: 20374351
[TBL] [Abstract][Full Text] [Related]
11. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
12. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
McKeown E; Bykerk VP; De Leon F; Bonner A; Thorne C; Hitchon CA; Boire G; Haraoui B; Ferland DS; Keystone EC; Pope JE;
Rheumatology (Oxford); 2012 Sep; 51(9):1662-9. PubMed ID: 22539481
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
14. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
Suzuki Y; Sato S
Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
[TBL] [Abstract][Full Text] [Related]
15. Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention.
Duyvendak M; Naunton M; van Roon EN; Brouwers JR
J Clin Pharm Ther; 2011 Jun; 36(3):356-66. PubMed ID: 21545615
[TBL] [Abstract][Full Text] [Related]
16. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting.
Yood RA; Harrold LR; Fish L; Cernieux J; Emani S; Conboy E; Gurwitz JH
Arch Intern Med; 2001 May; 161(10):1322-7. PubMed ID: 11371261
[TBL] [Abstract][Full Text] [Related]
17. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.
Mudano A; Allison J; Hill J; Rothermel T; Saag K
J Rheumatol; 2001 Jun; 28(6):1298-305. PubMed ID: 11409123
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
Soen S
Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
[TBL] [Abstract][Full Text] [Related]
19. Trends in prevention of glucocorticoid-induced osteoporosis.
Saag KG; Gehlbach SH; Curtis JR; Youket TE; Worley K; Lange JL
J Rheumatol; 2006 Aug; 33(8):1651-7. PubMed ID: 16845707
[TBL] [Abstract][Full Text] [Related]
20. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
